RANI News and Press, Rani Therapeutics Holdings Inc. From 04/17/24

A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 62.9% to $0.0373 on volume of 466,310,671 shares INVO BioScience Inc. (INVO) rose 139.5% to $1.82 on volume of 225,666,770 shares PROSHARES TRUST (SQQQ) rose 3.7% to $11.86 on volume of 167,545,988 ...

A look at the top 10 most actives in the United States Jaguar Health Inc. (JAGX) rose 50.1% to $0.1783 on volume of 599,794,977 shares WiSA Technologies Inc. (WISA) rose 248.6% to $6.1 on volume of 197,912,579 shares PROSHARES TRUST (SQQQ) rose 0.0% to $11.44 on volume of 182,001,060 shar...

2024-03-27 08:15:03 ET Canaccord Genuity analyst issues BUY recommendation for RANI on March 27, 2024 06:44AM ET. The previous analyst recommendation was Buy. RANI was trading at $3.18 at issue of the analyst recommendation. Historical Analyst Recommendations Lates...

2024-03-20 19:05:06 ET Rani Therapeutics Holdings, Inc. (RANI) Q4 2023 Earnings Conference Call March 20, 2024, 04:30 PM ET Company Participants Kiki Patel - Gilmartin Group LLC Talat Imran - Chief Executive Officer Arvinder Dhalla - Vice President, Clinical ...

2024-03-20 16:17:53 ET More on Rani Therapeutics Seeking Alpha’s Quant Rating on Rani Therapeutics Historical earnings data for Rani Therapeutics Financial information for Rani Therapeutics Read the full article on Seeking Alpha For further det...

- Announced Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) - - Announced Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist - - Cash runway extended into 2025 - - Conference call and web...

Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...

SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release ...

2024-02-05 08:31:42 ET Chenghe Acquisition  ( CHEA ) +153% . 4D Molecular Therapeutics ( FDMT ) +54% . BioRestorative Therapies  ( BRTX ) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease. ...

2024-02-05 08:25:25 ET More on pre-market losers & stocks. Livent: Undervalued With Significant Upside Potential Livent: Wonderful Company Fairly Valued Livent And Albemarle: 2 Lithium Stocks To Buy Now Livent and Allkem shareholders approve merger of equ...